 |
|
JAMA-EXPRESS
Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical AtherosclerosisThe METEOR Trial
John R. Crouse III, MD;
Joel S. Raichlen, MD;
Ward A. Riley, PhD;
Gregory W. Evans, MA;
Mike K. Palmer, PhD;
Daniel H. O’Leary, MD;
Diederick E. Grobbee, MD, PhD;
Michiel L. Bots, MD, PhD; for the METEOR Study Group
JAMA. 2007;297:(doi:10.1001/jama.297.12.1344).
Context Atherosclerosis is often advanced before symptoms appear and it is not clear whether treatment is beneficial in middle-aged individuals with a low Framingham risk score (FRS) and mild to moderate subclinical atherosclerosis.
Objective To assess whether statin therapy could slow progression and/or cause regression of carotid intima-media thickness (CIMT) over 2 years.
Design, Setting, and Participants Randomized, double-blind, placebo-controlled study (Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin [METEOR]) of 984 individuals, with either age (mean, 57 years) as the only coronary heart disease risk factor or a 10-year FRS of less than 10%, modest CIMT thickening (1.2-<3.5 mm), and elevated LDL cholesterol (mean, 154 mg/dL); conducted at 61 primary care centers in the United States and Europe between August 2002 and May 2006.
Intervention Participants received either a 40-mg dose of rosuvastatin or placebo.
Main Outcome Measures Rate of change in maximum CIMT (assessed with B-mode ultrasound) for 12 carotid sites; changes in maximum CIMT of the common carotid artery, carotid bulb, and internal carotid artery sites and in mean CIMT of the common carotid artery sites. CIMT regression was assessed in the rosuvastatin group only.
Results Among participants in the rosuvastatin group, the mean (SD) baseline LDL cholesterol level of 155 (24.1) mg/dL declined to 78 (27.5) mg/dL, a mean reduction of 49% (P<.001 vs placebo group). The change in maximum CIMT for the 12 carotid sites was –0.0014 (95% CI, –0.0041 to 0.0014) mm/y for the rosuvastatin group vs 0.0131 (95% CI, 0.0087-0.0174) mm/y for the placebo group (P<.001). The change in maximum CIMT for the rosuvastatin group was –0.0038 (95% CI, –0.0064 to –0.0013) mm/y for the common carotid artery sites (P<.001), –0.0040 (95% CI, –0.0090 to 0.0010) mm/y for the carotid bulb sites (P<.001), and 0.0039 (95% CI, –0.0009 to 0.0088) mm/y for the internal carotid artery sites (P = .02). The change in mean CIMT for the rosuvastatin group for the common carotid artery sites was 0.0004 (95% CI, –0.0011 to 0.0019) mm/y (P<.001). All P values are vs placebo group. Overall, rosuvastatin was well tolerated with infrequent serious adverse cardiovascular events (6 participants [0.86%] had 8 events [1.1%] over 2 years).
Conclusions In middle-aged adults with an FRS of less than 10% and evidence of subclinical atherosclerosis, rosuvastatin resulted in statistically significant reductions in the rate of progression of maximum CIMT over 2 years vs placebo. Rosuvastatin did not induce disease regression. Larger, longer-term trials are needed to determine the clinical implications of these findings.
Trial Registration clinicaltrials.gov Identifier: NCT00225589
Published online March 25, 2007 (doi:10.1001/jama.297.12.1344).
Author Affiliations: Departments of Medicine (Dr Crouse), Neurology (Dr Riley), and Public Health Sciences (Mr Evans), Wake Forest University, Winston-Salem, NC; AstraZeneca, Wilmington, Del (Dr Raichlen); AstraZeneca, Macclesfield, England (Dr Palmer); Caritas Carney Hospital, Boston, Mass (Dr O’Leary); and Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands (Drs Grobbee and Bots).
RELATED ARTICLE
Primary Prevention of Atherosclerotic Cardiovascular Disease: The High Public Burden of Low Individual Risk
Michael S. Lauer
JAMA. 2007;297(12):1376-1378.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
An Overview of the Extra-Lipid Effects of Rosuvastatin
Kostapanos et al.
J CARDIOVASC PHARMACOL THER 2008;13:157-174.
ABSTRACT
Carotid Intima--Media Thickness (cIMT): A Useful Clinic Tool or Research Luxury? Another View of the ENHANCE Trial
Toutouzas and Richter
ANGIOLOGY 2008;59:77S-79S.
ABSTRACT
Rosuvastatin and Cardiovascular Disease: Did the Strongest Statin Hold the Initial Promises?
Efthimiadis
ANGIOLOGY 2008;59:62S-64S.
ABSTRACT
Vascular form and function: two mechanisms for cardiovascular prevention
Kinlay
Eur Heart J 2008;29:1711-1713.
FULL TEXT
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications
DAVIDSON
Cleveland Clinic Journal of Medicine 2008;75:479-496.
FULL TEXT
Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT
| FULL TEXT
Ultrasound imaging techniques for the evaluation of cardiovascular therapies
Kastelein and de Groot
Eur Heart J 2008;29:849-858.
ABSTRACT
| FULL TEXT
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2008;51:944-955.
FULL TEXT
Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes
Peters
Clin. Diabetes 2008;26:3-7.
ABSTRACT
| FULL TEXT
Highlights of the 56th Annual Scientific Session of the American College of Cardiology, March 24-27, 2007. ACC.07 and i2 Summit Highlights: A Conversation With the Experts.
Tuzcu et al.
J Am Coll Cardiol 2007;50:C2-31.
FULL TEXT
JournalScan
Lindsay
Heart 2007;93:1008-1010.
FULL TEXT
Voodoo medicine -- cardiovascular trials jinxed in New Orleans: Dr Anthony Wierzbicki discusses highlights of the 56th Annual Scientific Session of American College of Cardiology held at Morial Conventions Centre in New Orleans March 24th--27th, 2007
Wierzbicki
British Journal of Diabetes & Vascular Disease 2007;7:142-144.
METEOR: Does Rosuvastatin Benefit Low-Risk Patients?
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT
Primary Prevention of Atherosclerotic Cardiovascular Disease: The High Public Burden of Low Individual Risk
Lauer
JAMA 2007;297:1376-1378.
FULL TEXT
|
